Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PB-TX-01
- Development stage
- Phase 2
- Lead developer
- PathoBlock Therapeutics
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
PB-TX-01 is a topical powder formulation containing the monosaccharides l-fucose and d-galactose, developed by PathoBlock Therapeutics for the treatment of chronic wounds colonized by *Pseudomonas aeruginosa*. The drug acts as a bacterial virulence inhibitor (pathoblocker) by targeting the bacterial lectins LecA (PA-I galactophilic lectin) and LecB (fucose-binding lectin PA-IIL). By binding to these lectins, PB-TX-01 prevents the adhesion of *P. aeruginosa* to host cells, disrupts biofilm formation, and facilitates bacterial clearance without directly killing the bacteria, thereby minimizing the risk of developing antimicrobial resistance. It is currently in Phase II clinical development in Germany.
- Other names
- elfucose + d-galactosel-fucose + d-galactose
02
Targets
P. aeruginosa (Pseudomonas aeruginosa)LecA (PA-I galactophilic lectin)
Beyond the preview
Go deeper on PB-TX-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PB-TX-01.